Tempest aims to explore strategic alternatives for advancing pipeline studies that maximize shareholder value. Stock rises in ...

Tempest Therapeutics hires MTS Health to explore M&A and partnerships after Roche shows limited interest in its liver cancer ...

Scotiabank analyst George Farmer downgraded Tempest Therapeutics (TPST) to Sector Perform from Outperform with a reverse stock-split adjusted ...

H.C. Wainwright downgraded Tempest Therapeutics (TPST) to Neutral from Buy without a price target after the company announced it is seeking to ...

Explore Tempest Therapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for TPST. Tempest Therapeutics enters a Phase 3 trial for its liver cancer drug ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The stock options will vest over a four-year BRISBANE, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first ...

We have seen 20 institutional investors add shares of $TPST stock to their portfolio, and 13 decrease their positions in their most recent quarter.